SG
GLMD icon

StoneX Group’s Galmed Pharmaceuticals GLMD Stock Holding History

StoneX Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-59
Closed -$5.28K – 554
2022
Q4 		$5.28K Buy
+59
New +$3.86K ﹤0.01% 492

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

StoneX Group's GLMD Position: Q1 2023 in Review

StoneX Group sold out of Galmed Pharmaceuticals (GLMD) in Q1 2023, closing a stake of 59 shares — an estimated $5.28K sold.

StoneX Group first reported a position in GLMD in Q4 2022 and held it in 1 quarter. The position peaked at $5.28K in Q4 2022. 20 funds tracked by Wall St. Rank hold GLMD as of Q1 2023.

  • StoneX Group reported no remaining Galmed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 59 Galmed Pharmaceuticals shares in Q1 2023, an estimated $5.28K.
  • StoneX Group first reported a position in Galmed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Galmed Pharmaceuticals position peaked at $5.28K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.